ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer

Li, Qing; Zhou, Zhi-Wei; Lu, Jia; Luo, Hao; Wang, Shu-Nan; Peng, Yu; Deng, Meng-Sheng; Song, Guan-Bin; Wang, Jian-Min; Wei, Xi; Wang, Dong*; Westover, Kenneth D.*; Xu, Cheng-Xiong*重庆大学
Molecular Therapy2022-2-2DOI: 10.1016/j.ymthe.2021.09.013
13被引9阅读
引用收藏
分享

摘要

Cancer cells evade immune detection via programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) interactions that inactivate T cells. PD-1/PD-L1 blockade has become an important therapy in the anti-cancer armamentarium. However, some patients do not benefit from PD-1/ PD-L1 blockade despite expressing PD-L1. Here, we screened 101 gastric cancer (GC) patients at diagnosis and 141 healthy control subjects and reported one such subpopulation of GC patients with rs17718883 polymorphism in PD-L1, resulting in a nonsense P146R mutation. We detected rs17718883 in 44% of healthy control subjects, and rs17718883 was associated with a low susceptibility to GC and better prognosis in GC patients. Structural analysis suggests that the mutation weakens the PD-1:PD-L1 interaction. This was supported by co-culture experiments of T cells, with GC cells showing that the P146R substitution results in interferon (IFN)-g secretion by T cells and enables T cells to suppress GC cell growth. Similar results with animal gastric tumor models were obtained in vivo. PD-1 monoclonal antibody treatment did not enhance the inhibitory effect of T cells on GC cells expressing PD-L1P146R in vitro or in vivo. This study suggests that rs17718883 is common and may be used as a biomarker for exclusion from PD-1/PD-L1 blockade therapy.

学科与关键词

关键词
POLYMORPHISMS
相关
加载中…
  • Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients
    Chen, Xinhua; Zhang, Huimin; Wang, Minghao; Liu, Hao; Hu, Yanfeng; Lin, Tian; Chen, Hao; Zhao, Mingli; Chen, Tao; Li, Guoxin; Yu, Jiang*; Zhao, Liying*Frontiers in Immunology, 2022, 13: 783695.被引 7
  • Fibroblast-derived LPP as a biomarker for treatment response and therapeutic target in gastric cancer
    Wang, Hao; Wu, Jing; Ling, Ruoyu; Li, Fengping; Yang, Qingbin; He, Jiayong; Lei, Xuetao; Wu, Chaorui; Zhang, Guofan; Zheng, Boyang; Peng, Yanmei; Zhang, Yihao; Chen, Hao*; Ye, Gengtai*; Li, Guoxin*Molecular Therapy-Oncolytics, 2022, 24: 547-560.被引 5
  • The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
    Chen, Li; Zhao, Ruihu; Sun, Hao; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*Frontiers in Pharmacology, 2022, 13: 833584.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Therapy
发表日期
2022-02-02
卷期
第 30 卷, 第 2 期
页码
621-631
DOI
10.1016/j.ymthe.2021.09.013
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Science and Technology Innovation Enhancement Project of Army Medical University (STIEP) [2019XLC3052]; National Natural Science Foundation of China [81772495]; NIH [P30CA142543]

作者

  • L

    Li, Qing (第一作者)

    chongqing univ

  • Z

    Zhou, Zhi-Wei

查看全部 13 位作者收起作者
  • L

    Lu, Jia

  • L

    Luo, Hao

    chongqing univ

  • W

    Wang, Shu-Nan

  • P

    Peng, Yu

  • D

    Deng, Meng-Sheng

  • S

    Song, Guan-Bin

    chongqing univ

  • W

    Wang, Jian-Min

  • W

    Wei, Xi

    tianjin med univ canc inst & hosp

  • W

    Wang, Dong (通讯)

  • W

    Westover, Kenneth D. (通讯)

  • X

    Xu, Cheng-Xiong (通讯)

    chongqing univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417